SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

23 Jan 2024 Evaluate
The revenue slipped marginally during the December 2023 quarter. A decline of about Rs. 1613.35 millions was observed as compared to Rs. 1687.92 millions during the corresponding quarter last year.The Net Profit of the company registered a slight decline of -29.24% to Rs. 207.19  millions from Rs. 292.80 millions.The company reported a degrowth in operating Profit to 365.56 millions from 448.84 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 1613.35 1687.92 -4.42 4416.42 4549.21 -2.92 5983.40 6363.57 -5.97
Other Income 78.97 114.23 -30.87 250.38 442.88 -43.47 507.66 326.28 55.59
PBIDT 365.56 448.84 -18.55 1070.56 1235.31 -13.34 1409.21 1418.26 -0.64
Interest 17.88 12.03 48.63 42.75 50.84 -15.91 100.57 43.24 132.59
PBDT 347.68 436.81 -20.40 1027.81 1184.47 -13.23 1308.64 1402.47 -6.69
Depreciation 62.48 37.90 64.85 172.90 111.99 54.39 151.73 138.47 9.58
PBT 285.20 398.91 -28.51 854.91 1072.48 -20.29 1156.91 1264.00 -8.47
TAX 78.01 106.11 -26.48 233.85 278.77 -16.11 302.14 337.36 -10.44
Deferred Tax 13.84 -12.71 -208.89 22.13 -17.41 -227.11 -42.10 7.68 -648.18
PAT 207.19 292.80 -29.24 621.06 793.71 -21.75 854.77 926.64 -7.76
Equity 104.69 104.15 0.52 104.69 104.15 0.52 104.15 103.68 0.45
PBIDTM(%) 22.66 26.59 -14.79 24.24 27.15 -10.73 23.55 22.29 5.68

Bliss GVS Pharma Share Price

258.35 -0.95 (-0.37%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×